1 completed, 1 not yet recruiting, 1 terminated, 1 withdrawn. 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Equillium: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of EQ504 in Single and Multiple Ascending Doses in Healthy Volunteers EQ504, EQ504 Placebo - Ulcerative Colitis | Phase 1 | Not yet recruiting | Equillium | 70 | 2026-10-01 | 2026-10-09 |
| Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata EQ101 - Alopecia Areata, Alopecia | Phase 2 | Completed | Equillium | 36 | 2022-12-19 | 2025-04-10 |
| A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) Itolizumab, EQ001 Placebo - Graft Versus Host Disease, GVHD | Phase 3 | Terminated | Equillium | 158 | 2022-04-29 | 2025-06-17 |
| Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata BNZ-1, Normal saline - Alopecia Areata, Alopecia Totalis | Phase 2 | Withdrawn | Equillium | 2021-10-01 | 2022-09-16 |
Alopecia Areata (2) · Alopecia universalis (2) · Alopecia (1) · Colitis, Ulcerative (1) · Graft vs Host Disease (1)
Saline Solution (1) · itolizumab (1)
Australia (3) · New Zealand (2) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Portugal (1) · South Korea (1) · Spain (1) · United States (1)